Royal Bank of Canada’s Tvardi Therapeutics TVRD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $0 | Sell |
85
-209
| -71% | -$819 | ﹤0.01% | 7875 |
|
|
2025
Q4 | $1K | Sell |
294
-2,375
| -89% | -$21.3K | ﹤0.01% | 7094 |
|
|
2025
Q3 | $104K | Buy |
2,669
+2,403
| +903% | +$68.4K | ﹤0.01% | 5491 |
|
|
2025
Q2 | $6K | Buy |
266
+253
| +1,946% | +$5.98K | ﹤0.01% | 6620 |
|
|
2025
Q1 | $0 | Sell |
13
-8
| -38% | -$121 | ﹤0.01% | 7359 |
|
|
2024
Q4 | $0 | Buy |
21
+9
| +75% | +$98 | ﹤0.01% | 7358 |
|
|
2024
Q3 | $0 | Sell |
12
-114
| -90% | -$1.34K | ﹤0.01% | 7616 |
|
|
2024
Q2 | $1K | Buy |
126
+84
| +200% | +$2K | ﹤0.01% | 6938 |
|
|
2024
Q1 | $1K | Sell |
42
-389
| -90% | -$10.1K | ﹤0.01% | 6899 |
|
|
2023
Q4 | $10K | Buy |
431
+200
| +87% | +$8.28K | ﹤0.01% | 6508 |
|
|
2023
Q3 | $14K | Buy |
231
+83
| +56% | +$7.79K | ﹤0.01% | 6326 |
|
|
2023
Q2 | $15K | Buy |
148
+44
| +42% | +$6.06K | ﹤0.01% | 6339 |
|
|
2023
Q1 | $18K | Sell |
104
-86
| -45% | -$28.8K | ﹤0.01% | 6075 |
|
|
2022
Q4 | $73K | Buy |
190
+94
| +98% | +$35.7K | ﹤0.01% | 5674 |
|
|
2022
Q3 | $32K | Buy |
96
+18
| +23% | +$6.52K | ﹤0.01% | 5954 |
|
|
2022
Q2 | $25K | Sell |
78
-84
| -52% | -$29.5K | ﹤0.01% | 6014 |
|
|
2022
Q1 | $70K | Sell |
162
-104
| -39% | -$42.7K | ﹤0.01% | 5872 |
|
|
2021
Q4 | $116K | Buy |
266
+77
| +41% | +$38.7K | ﹤0.01% | 5829 |
|
|
2021
Q3 | $105K | Buy |
189
+21
| +13% | +$10.5K | ﹤0.01% | 5665 |
|
|
2021
Q2 | $86K | Buy |
168
+39
| +30% | +$24.7K | ﹤0.01% | 5709 |
|
|
2021
Q1 | $101K | Buy |
129
+52
| +68% | +$35.6K | ﹤0.01% | 5458 |
|
|
2020
Q4 | $42K | Sell |
77
-12
| -13% | -$6.29K | ﹤0.01% | 5738 |
|
|
2020
Q3 | $41K | Sell |
89
-1
| -1% | -$581 | ﹤0.01% | 5430 |
|
|
2020
Q2 | $56K | Buy |
90
+2
| +2% | +$1.1K | ﹤0.01% | 5176 |
|
|
2020
Q1 | $41K | Sell |
88
-50
| -36% | -$27.2K | ﹤0.01% | 5260 |
|
|
2019
Q4 | $81K | Buy |
138
+95
| +221% | +$66.7K | ﹤0.01% | 5200 |
|
|
2019
Q3 | $29K | Sell |
43
-6
| -12% | -$4.99K | ﹤0.01% | 5346 |
|
|
2019
Q2 | $38K | Sell |
49
-2
| -4% | -$1.41K | ﹤0.01% | 5418 |
|
|
2019
Q1 | $36K | Buy |
51
+2
| +4% | +$1.2K | ﹤0.01% | 5353 |
|
|
2018
Q4 | $23K | Sell |
49
-47
| -49% | -$30.3K | ﹤0.01% | 5527 |
|
|
2018
Q3 | $82K | Sell |
96
-15
| -14% | -$10.8K | ﹤0.01% | 4972 |
|
|
2018
Q2 | $77K | Sell |
111
-3
| -3% | -$1.52K | ﹤0.01% | 4959 |
|
|
2018
Q1 | $50K | Sell |
114
-67
| -37% | -$32.5K | ﹤0.01% | 5058 |
|
|
2017
Q4 | $79K | Buy |
181
+26
| +17% | +$11.9K | ﹤0.01% | 4945 |
|
|
2017
Q3 | $77K | Buy |
155
+96
| +163% | +$48.1K | ﹤0.01% | 5187 |
|
|
2017
Q2 | $32K | Sell |
59
-26
| -31% | -$16.5K | ﹤0.01% | 5334 |
|
|
2017
Q1 | $56K | Buy |
85
+31
| +57% | +$16.6K | ﹤0.01% | 5089 |
|
|
2016
Q4 | $18K | Buy |
54
+27
| +100% | +$8.66K | ﹤0.01% | 5837 |
|
|
2016
Q3 | $8K | Hold |
27
| – | – | ﹤0.01% | 5859 |
|
|
2016
Q2 | $5K | Buy |
27
+13
| +93% | +$2.83K | ﹤0.01% | 5959 |
|
|
2016
Q1 | $3K | Hold |
14
| – | – | ﹤0.01% | 6064 |
|
|
2015
Q4 | $8K | Sell |
14
-13
| -48% | -$7.14K | ﹤0.01% | 6044 |
|
|
2015
Q3 | $14K | Sell |
27
-6
| -18% | -$4.02K | ﹤0.01% | 5730 |
|
|
2015
Q2 | $14K | Buy |
+33
| New | +$12.8K | ﹤0.01% | 5904 |
|
Other funds holding TVRD
SPC
VCM
AFG
SAM
DWAM
Royal Bank of Canada's TVRD Position: Q1 2026 in Review
Royal Bank of Canada reduced its Tvardi Therapeutics (TVRD) stake by 71% in Q1 2026, selling an estimated $819 and leaving 85 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #7875.
Royal Bank of Canada first reported a position in TVRD in Q2 2015 and has held it in 44 quarters since. The position peaked at $116K in Q4 2021. 67 funds tracked by Wall St. Rank hold TVRD as of Q1 2026.
- Royal Bank of Canada held 85 shares of Tvardi Therapeutics worth $0 as of Q1 2026.
- Royal Bank of Canada sold 209 Tvardi Therapeutics shares in Q1 2026, an estimated $819.
- Tvardi Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #7875 holding.
- Royal Bank of Canada first reported a position in Tvardi Therapeutics in Q2 2015 and has held it in 44 quarters since.
- Royal Bank of Canada's Tvardi Therapeutics position peaked at $116K in Q4 2021.
- 67 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q1 2026.
Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.